

## DIGESTIVE SYSTEM

ISSUE DATE: August 26, 1985

AUTHORITY: 32 CFR 199.4(c)(2) and (c)(3)

---

### I. CPT<sup>1</sup> PROCEDURE CODES

40490 - 40831, 40899 - 43644, 43647, 43648, 43651 - 43761, 43800, 43810, 43820, 43842, 43846, 43848, 43880 - 43882, 43999, 44005 - 47362, 47370, 47371, 47379 - 47382, 47399 - 49999, 91123, 96570, 96571

### II. DESCRIPTION

The digestive system involves the organs associated with the ingestion, digestion, and absorption of nutrients, and the elimination of solid waste.

### III. POLICY

A. Services and supplies required in the diagnosis and treatment of illness or injury involving the digestive system are covered.

B. Gastric electrical stimulation (CPT<sup>1</sup> procedure codes 43647, 43648, 43881, and 43882) for treatment of symptoms of nausea and vomiting from chronic gastroparesis that is refractory to medical management may be considered for coverage as a Humanitarian Use Device (HUD).

C. Radiofrequency Ablation (RFA) (CPT<sup>1</sup> procedure codes 47370, 47380, and 47382) for treatment of unresectable hepatocellular carcinoma or unresectable liver metastases from colorectal cancer is proven and may be covered when all of the following conditions are met:

1. Tumors are less than five centimeters in diameter;
2. There are five or fewer tumors; and
3. There is no evidence of extrahepatic metastasis.

All procedures must be performed using an Food and Drug Administration (FDA) approved electrosurgical cutting and coagulation device.

---

<sup>1</sup> CPT only © 2006 American Medical Association (or such other date of publication of CPT). All Rights Reserved.

D. Intraperitoneal Hyperthermic Chemotherapy (IPHC) (CPT<sup>2</sup> procedure codes 77600, 77605, and 96445) in conjunction with cytoreductive surgery or peritonectomy for treatment of pseudomyxoma peritonei resulting from appendiceal carcinoma may be covered under the Rare Diseases policy on a case-by-case basis for adult patients when all of the following criteria are met:

1. There is no evidence of distant metastasis.
2. There is evidence of low histological aggressiveness of the disease.
3. The patient has not undergone preoperative systemic chemotherapy.
4. The patient's condition does not preclude major surgery.
5. The chemotherapeutic agents used are mitomycin C, cisplatin (also known as cisplatinum), or fluorouracil.

E. Transanal Endoscopic Microsurgery (TEM) (CPT<sup>2</sup> procedure code 0184T) for treatment of benign lesions or malignant T1 tumors is proven and may be covered when all of the following criteria are met:

1. The lesion can be adequately identified in the rectum and is a mobile, non-fixed benign lesion or T1 tumor with a diameter less than three centimeters that covers less than 30% of the circumference of the bowel, located within eight centimeters of the anal verge.
2. Pretreatment endorectal ultrasonography indicates an absence of lymphadenopathy and microscopic angiolymphatic invasion.
3. The tumor is a moderately or well differentiated grade I, with no lymphatic, vascular, or perineural invasion.
4. Resection margins are negative for greater than three millimeters.
5. There is no evidence of distant metastasis.

#### IV. EXCLUSIONS

A. Vestibuloplasty (CPT<sup>2</sup> procedure code range 40840-40845) EXCEPT for adjunctive dental care ([Chapter 8, Section 13.1](#)).

B. The Stretta System (Curon Medical, Sunnyvale, CA), and Bard Endoscopic Suturing System, and Transoral Incisionless Fundoplication using EsophyX (EndoGastric Solutions, Redmond, WA) for the treatment of refractory Gastro-Esophageal Reflux Disease (GERD) are unproven (CPT<sup>2</sup> procedure codes 43201 and 43257).

C. For bariatric procedures, see [Section 13.2](#).

<sup>2</sup> CPT only © 2006 American Medical Association (or such other date of publication of CPT). All Rights Reserved.

D. RFA for treatment of liver metastases from primary sites other than colorectal metastases is unproven (CPT<sup>3</sup> procedure codes 47370, 47380, and 47382).

E. Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for treatment of Peritoneal Carcinomatosis (PC) from colorectal cancer.

V. EFFECTIVE DATES

A. RFA (CPT<sup>3</sup> procedure codes 47370, 47380, and 47382) for treatment of unresectable hepatocellular carcinoma or unresectable liver metastases from colorectal cancer is proven and covered, effective April 28, 2004.

B. IPHC (CPT<sup>3</sup> procedure codes 77600, 77605, and 96445) in conjunction with cytoreductive surgery or peritonectomy for treatment of pseudomyxoma peritonei arising from appendiceal carcinoma may be covered under the Rare Diseases policy on a case-by-case basis for adult patients, effective May 13, 2009.

C. TEM (CPT<sup>3</sup> procedure code 0184T) for treatment of benign lesions or malignant T1 tumors is covered effective June 2, 2009.

- END -

---

<sup>3</sup> CPT only © 2006 American Medical Association (or such other date of publication of CPT). All Rights Reserved.

